Nelson Vergel
Founder, ExcelMale.com
The U.S. Food and Drug Administration today approved Contrave (naltrexone hydrochloride and bupropion hydrochloride extended-release tablets) as treatment option for chronic weight management in addition to a reduced-calorie diet and physical activity.
The drug is approved for use in adults with a body mass index (BMI) of 30 or greater (obesity) or adults with a BMI of 27 or greater (overweight) who have at least one weight-related condition such as high blood pressure (hypertension), type 2 diabetes, or high cholesterol (dyslipidemia).
BMI, which measures body fat based on an individual's weight and height, is used to define the obesity and overweight categories. According to the Centers for Disease Control and Prevention, more than one-third of adults in the United States are obese.
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm413896.htm
Contrave is a combo of two old drugs: Wellbutrin (generic: bupropion- an antidepressant also prescribed to help to quit smoking) and naltrexone (prescribed for alcohol and opiate addiction). In combination they synergistically reduce the cravings for food. But some people may get anxiety or have increased heart rate (mostly due to the bupropion).
These are the previously approved weight loss drugs in the United States:
Top 5 FDA Approved Diet Pills
Last edited:
